Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

CONTEXT Osteoporosis is associated with significant morbidity and mortality. Oral bisphosphonates have become a mainstay of treatment, but concerns have emerged that long-term use of these drugs may suppress bone remodeling, leading to unusual fractures. OBJECTIVE To determine whether prolonged bisphosphonate therapy is associated with an increased risk of subtrochanteric or femoral shaft fracture. DESIGN, SETTING, AND PATIENTS A population-based, nested case-control study to explore the association between bisphosphonate use and fractures in a cohort of women aged 68 years or older from Ontario, Canada, who initiated therapy with an oral bisphosphonate between April 1, 2002, and March 31, 2008. Cases were those hospitalized with a subtrochanteric or femoral shaft fracture and were matched to up to 5 controls with no such fracture. Study participants were followed up until March 31, 2009. MAIN OUTCOME MEASURES The primary analysis examined the association between hospitalization for a subtrochanteric or femoral shaft fracture and duration of bisphosphonate exposure. To test the specificity of the findings, the association between bisphosphonate use and fractures of the femoral neck or intertrochanteric region, which are characteristic of osteoporotic fractures, was also examined. RESULTS We identified 716 women who sustained a subtrochanteric or femoral shaft fracture following initiation of bisphosphonate therapy and 9723 women who sustained a typical osteoporotic fracture of the intertrochanteric region or femoral neck. Compared with transient bisphosphonate use, treatment for 5 years or longer was associated with an increased risk of subtrochanteric or femoral shaft fracture (adjusted odds ratio, 2.74; 95% confidence interval, 1.25-6.02). A reduced risk of typical osteoporotic fractures occurred among women with more than 5 years of bisphosphonate therapy (adjusted odds ratio, 0.76; 95% confidence interval, 0.63-0.93). Among 52,595 women with at least 5 years of bisphosphonate therapy, a subtrochanteric or femoral shaft fracture occurred in 71 (0.13%) during the subsequent year and 117 (0.22%) within 2 years. CONCLUSION Among older women, treatment with a bisphosphonate for more than 5 years was associated with an increased risk of subtrochanteric or femoral shaft fractures; however, the absolute risk of these fractures is low.

[1]  T. Anastassiades,et al.  The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study , 2008, Osteoporosis International.

[2]  B. Steele,et al.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.

[3]  S. Cole,et al.  A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression , 2009, Cancer Epidemiology Biomarkers & Prevention.

[4]  P. Tugwell,et al.  Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.

[5]  M. Goldacre,et al.  Secular trends in proximal femoral fracture, Oxford record linkage study area and England 1968-86. , 1997, Journal of epidemiology and community health.

[6]  Paul Grootendorst,et al.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[7]  R. Goodman,et al.  The effect of risedronate on the risk of hip fracture in elderly women. , 2001, The New England journal of medicine.

[8]  A. Laupacis,et al.  Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study , 2009, PLoS medicine.

[9]  Diane C. Tsai.  Methods in Observational Epidemiology , 1988, The Yale Journal of Biology and Medicine.

[10]  E. Badley,et al.  Socioeconomic Misclassification in Ontario’s Health Care Registry , 2003, Canadian journal of public health = Revue canadienne de sante publique.

[11]  A. Westfall,et al.  Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday , 2008, Osteoporosis International.

[12]  J. Cramer,et al.  A systematic review of persistence and compliance with bisphosphonates for osteoporosis , 2007, Osteoporosis International.

[13]  Cathleen S. Colón-Emeric,et al.  Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men , 2010, Annals of Internal Medicine.

[14]  J. Schneider.  Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. , 2009, Geriatrics.

[15]  C. Cooper,et al.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report , 2010, Osteoporosis International.

[16]  C. Weinberg,et al.  Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. , 1998, American journal of epidemiology.

[17]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Ego Seeman,et al.  To stop or not to stop, that is the question , 2009, Osteoporosis International.

[19]  L. Nordsletten,et al.  Local and national electronic databases in Norway demonstrate a varying degree of validity. , 2005, Journal of clinical epidemiology.

[20]  G. Hawker,et al.  Hip fractures in users of first- vs. second-generation bisphosphonates , 2007, Osteoporosis International.

[21]  E. Shane.  Evolving data about subtrochanteric fractures and bisphosphonates. , 2010, The New England journal of medicine.

[22]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[23]  Lehana Thabane,et al.  Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study , 2009, Canadian Medical Association Journal.

[24]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[25]  C. Colón-Emeric.  Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. , 2006, JAMA.

[26]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[27]  Michael P. Kelly,et al.  Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. , 2010, The New England journal of medicine.

[28]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[29]  P. Geusens.  Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment , 2009, Current osteoporosis reports.

[30]  Alexander Kopp,et al.  Outpatient gatifloxacin therapy and dysglycemia in older adults. , 2006, The New England journal of medicine.

[31]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[32]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[33]  J. Robins,et al.  More on "Biased selection of controls for case-control analyses of cohort studies". , 1986, Biometrics.

[34]  M. Drake,et al.  Adverse effects of bisphosphonates: implications for osteoporosis management. , 2009, Mayo Clinic proceedings.

[35]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[36]  P. Tugwell,et al.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.

[37]  M. Swiontkowski.  Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study , 2010 .

[38]  J. Hanley.  A heuristic approach to the formulas for population attributable fraction , 2001, Journal of epidemiology and community health.

[39]  A. Laupacis,et al.  PERSISTENCE WITH BISPHOSPHONATE THERAPY IN OLDER PEOPLE , 2006, Journal of the American Geriatrics Society.

[40]  S. Vasikaran.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study , 2009, Osteoporosis International.

[41]  S. Haleem,et al.  Mortality following hip fracture: trends and geographical variations over the last 40 years. , 2008, Injury.

[42]  P. Tugwell,et al.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.

[43]  B. Clarke.  Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur , 2011 .